Gentronix is a biotechnology company that provides pharmaceutical makers with drug development products and monitoring services. Gentronix's products and services are geared toward helping drug discovery scientists speed up pre-clinical research and development. The company's main product, Greenscreen, uses cellular biosensor technology to test potential pharmaceutical compounds for genotoxicity (DNA damage) and cytotoxicity (general cellular damage). The company was founded in 1999 as part of the University of Manchester Institute of Science and Technology's Biomolecular Sciences and Instrumentation & Analytical Science departments.

Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France. Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. In its pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. On September 1, 2008, Sanofi-Aventis acquired the Australian company, Symbion CP Holdings Pty Ltd (Symbion Consumer). On September 25, 2008, it acquired Acambis plc. In January 2009, the Company sold its French plant of Colomiers to French pharmaceutical company Unither. In April 2009, the Company acquired Mexican generic company, Laboratorios Kendrick.

Sinclair Pharma can help those with itchy skin or bleeding gums. The specialty pharmaceutical development company acquires oral health and dermatology companies that have already begun developing products and turns them into new lines or line extensions for commercial sale. Its top sellers include Aloclair for mouth ulcers, Decapinol for gingivitis, and Atopiclair for ezcema. It has a sales presence in the UK, France, Italy, Portugal, and Spain, with marketing partners in more than 80 countries. When former CEO Michael Flynn led a management buy-in in 2000, Sinclair's strategy shifted from being a traditional early research and development company to an acquisition vehicle of late-stage development products.

International Brachytherapy (IBt) is planting the seeds of future health and vitality. IBt develops and markets interstitial implants -- commonly referred to as seeds -- used in brachytherapy to treat cancer. The radiotherapeutic implants are inserted inside or near cancerous tissue, delivering radioactive doses to tumors while sparing surrounding tissue. Founded in 1996, IBt operates from its Belgian headquarters as well as a US subsidiary, IBt Inc., and UK subsidiary IBt ltd. It also owns a majority stake in medical components provider Urorad GmbH.

Chesapeake Biological Laboratories (CBL) provides product development and commercial drug production services for pharmaceutical and biotechnology companies. It also manufactures experimental drugs for use in clinical trials. The company specializes in biopharmaceuticals, materials derived from naturally occurring biological substances. CBL's primary operations are sterilizing and filling liquid drugs and production lyophilization, the process of filling drug containers while limiting the product's exposure to room temperature. CBL is a wholly-owned subsidiary of Canadian biopharma firm Cangene.

Ranbaxy Pharmaceuticals Inc. company, the US arm of Indian generic pharmaceuticals giant Ranbaxy Laboratories Limited, makes and markets about 50 generic and over-the-counter (OTC) drugs. It accounts for about a quarter of its parent's annual revenues. RPI's generic offerings, produced by manufacturing subsidiary Ohm Laboratories, include anti-infectives and treatments for cardiovascular, gastrointestinal, and central nervous system disorders. Its OTC products include analgesics, antihistamines, and decongestants. Sister subsidiary Ranbaxy Laboratories, Inc. (RLI) develops branded pharmaceuticals.

Amazon Herb sells herbal supplements and other herbal products through a multilevel marketing network under the Rainforest Bio-Energetics brand. The company buys raw materials harvested by indigenous peoples of the rainforests in Peru; it contracts with third parties to make its products, then it packages them under its own label for sale in the US. Its products include herbal nutritional supplements, skin care products, cleaning supplies, and herbal pet-care remedies. Amazon company also sells raw materials in bulk to other manufacturers and donates 10% of its net profits for rain forest preservation.

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company’s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab. In March 2009, Roche Holding Ltd. completed the acquisition of Genentech.

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. Tablets and capsules can be immediate or time-release; the company also makes liquid formulations and provides specialty packaging, including laminated foil, blister, and pouches. Its facilities have the capacity to produce everything from small pilot-scale batches all the way up to full-scale commercial production. Other services include drug development, feasibility studies, and product testing. Mikart will also walk customers through all the required regulatory processes.

Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.